Cohort Profile: Chinese Cervical Cancer Clinical Study
- PMID: 34222018
- PMCID: PMC8250135
- DOI: 10.3389/fonc.2021.690275
Cohort Profile: Chinese Cervical Cancer Clinical Study
Abstract
Cervical cancer is the fourth most common cancer worldwide, but its incidence varies greatly in different countries. Regardless of incidence or mortality, the burden of cervical cancer in China accounts for approximately 18% of the global burden. The Chinese Cervical Cancer Clinical Study is a hospital-based multicenter open cohort. The major aims of this study include (i) to explore the associations of therapeutic strategies with complications as well as mid- and long-term clinical outcomes; (ii) to widely assess the factors which may have an influence on the prognosis of cervical cancer and then guide the treatment options, and to estimate prognosis using a prediction model for precise post-treatment care and follow-up; (iii) to develop a knowledge base of cervical clinical auxiliary diagnosis and prognosis prediction using artificial intelligence and machine learning approaches; and (iv) to roughly map the burden of cervical cancer in different districts and monitoring the trend in incidence of cervical cancer to potentially inform prevention and control strategies. Patients eligible for inclusion were those diagnosed with cervical cancer, whether during an outpatient visit or hospital admission, at 47 different types of medical institutions in 19 cities of 11 provinces across mainland China between 2004 and 2018. In a total, 63 926 patients with cervical cancer were enrolled in the cohort. Since the project inception, a large number of standardized variables have been collected, including epidemiological characteristics, cervical cancer-related symptoms, physical examination results, laboratory testing results, imaging reports, tumor biomarkers, tumor staging, tumor characteristics, comorbidities, co-infections, treatment and short-term complications. Follow-up was performed at least once every 6 months within the first 5 years after receiving treatment and then annually thereafter. At present, we are developing a cervical cancer imaging database containing Dicom files with data of computed tomography/magnetic resonance imaging examination. Additionally, we are also collecting original pathological specimens of patients with cervical cancer. Potential collaborators are welcomed to contact the corresponding authors, and anyone can submit at least one specific study proposal describing the background, objectives and methods of the study.
Keywords: cervical cancer; cohort; prediction; prognosis; therapy.
Copyright © 2021 Zhang, Li, Sun, Liu, Li, Li, Zhao, Chen, Ji, Wang, Kang, Lang, Mao and Chen.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4).Int J Epidemiol. 2014 Oct;43(5):1425-36. doi: 10.1093/ije/dyu002. Epub 2014 Feb 17. Int J Epidemiol. 2014. PMID: 24550249
-
Robotic total thyroidectomy with modified radical neck dissection via unilateral retroauricular approach.Ann Surg Oncol. 2014 Nov;21(12):3872-5. doi: 10.1245/s10434-014-3896-y. Epub 2014 Sep 17. Ann Surg Oncol. 2014. PMID: 25227305
-
Effects of short-term exposure to air pollution on hospital admissions of young children for acute lower respiratory infections in Ho Chi Minh City, Vietnam.Res Rep Health Eff Inst. 2012 Jun;(169):5-72; discussion 73-83. Res Rep Health Eff Inst. 2012. PMID: 22849236
-
Cervical cancer screening: A never-ending developing program.World J Clin Cases. 2015 Jul 16;3(7):614-24. doi: 10.12998/wjcc.v3.i7.614. World J Clin Cases. 2015. PMID: 26244153 Free PMC article. Review.
-
Anaplastic thyroid cancer: prevalence, diagnosis and treatment.Minerva Endocrinol. 2008 Dec;33(4):341-57. Minerva Endocrinol. 2008. PMID: 18923370 Review.
Cited by
-
Discussion on the rationality of FIGO 2018 stage IIIC for cervical cancer with oncological outcomes: a cohort study.Ann Transl Med. 2022 Jan;10(2):122. doi: 10.21037/atm-21-6374. Ann Transl Med. 2022. PMID: 35282078 Free PMC article.
-
Rationality of FIGO 2018 IIIC restaging of cervical cancer according to local tumor size: A cohort study.Acta Obstet Gynecol Scand. 2023 Aug;102(8):1045-1052. doi: 10.1111/aogs.14612. Epub 2023 Jun 20. Acta Obstet Gynecol Scand. 2023. PMID: 37338046 Free PMC article.
-
Survival Outcomes of Patients With Stage IB3 Cervical Cancer Who Undergo Abdominal Radical Hysterectomy Versus Radiochemotherapy.Front Oncol. 2022 Jul 6;12:933755. doi: 10.3389/fonc.2022.933755. eCollection 2022. Front Oncol. 2022. PMID: 35875125 Free PMC article.
-
Anti-HPV16 oncoproteins siRNA therapy for cervical cancer using a novel transdermal peptide PKU12.Front Oncol. 2023 Jun 7;13:1175958. doi: 10.3389/fonc.2023.1175958. eCollection 2023. Front Oncol. 2023. PMID: 37350944 Free PMC article.
References
-
- Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, et al. . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol (2018) 4:1553–68. 10.1001/jamaoncol.2018.2706 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources